الفهرس 
Introduction & Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 205 |  |  |
| | | from | 205 | | |
Abstract
Liver cirrhosis is considered the end stage of a variety of chronic liver diseases including chronic hepatitis C. Liver cirrhosis is irreversible in its advanced stages. The major complication of liver cirrhosis is HCC. HCC represents an increased cause of mortality, which most patients miss the best opportunity for treatment because of the lack of symptoms in the early stages.
AFP is considered the conventional tumor marker in cases of HCC but its level may increase in patients with other diseases such as LC. Also, AFP may not be elevated enough in HCC patients in early stages. Accordingly, finding another reliable tumor marker for HCC is required.
DCP has been found to increase in cases of HCC and in cases of HCC recurrence, Many studies has proved that DCP is obviously elevated in HCC patients compared with that in healthy adults and patients with non malignant hepatopathy. Thus serum DCP have been proved to be more useful than AFP in differentiating HCC from nonmalignant hepatopathy. Inspite of highly specificity of DCP, its sensitivity varies among the studies.
MICA is expressed in human tumor tissues and may participate in tumor development. sMICA might serve as a novel clinical marker in the diagnosis of HCC. Therefore, in this study we investigated the role of sMICA in HCC patients. Also, we compared between sMICA together with AFP and DCP in HCC, LC and chronic hepatitis patients.